CSF1R and pulmonary arterial hypertension: Seralutinib is a novel selective tyrosine kinase inhibitor that targets the PDGFRa/b, CSF1R, and c-kit pathways, which play a key role in the pathological inflammation and remodeling involved in PAH [66,67].